Subtopic Deep Dive
Molecular Subtyping of Urothelial Carcinoma
Research Guide
What is Molecular Subtyping of Urothelial Carcinoma?
Molecular subtyping of urothelial carcinoma classifies bladder tumors into luminal, basal, and other subtypes using genomics and transcriptomics to correlate with prognosis and therapy response.
TCGA analysis identified luminal and basal subtypes in urothelial bladder carcinoma (Weinstein et al., 2014, 2992 citations). Damrauer et al. (2014, 873 citations) described basal-like and luminal subtypes in high-grade bladder cancer mirroring breast cancer biology. Consensus meeting summarized overlapping subtype findings across studies (Lerner et al., 2016, 210 citations).
Why It Matters
Molecular subtyping guides precision medicine by stratifying patients for targeted therapies beyond staging. Basal subtypes show worse prognosis but potential immune checkpoint responsiveness (Damrauer et al., 2014; Wang et al., 2018). Luminal subtypes associate with FGFR3 mutations suitable for erdafitinib (Weinstein et al., 2014). Lindskrog et al. (2021) identified prognostic subtypes in non-muscle-invasive disease, enabling risk-adapted management.
Key Research Challenges
Subtype Consensus Variability
Different studies yield partially overlapping subtypes due to varied omics platforms and cohorts (Lerner et al., 2016). TCGA used mRNA while others incorporated methylation or protein data (Weinstein et al., 2014). Standardization remains unresolved.
Non-Muscle-Invasive Subtyping
High-grade muscle-invasive focus leaves non-muscle-invasive subtyping underdeveloped despite heterogeneity (Lindskrog et al., 2021). Multi-omics integration reveals prognostic clusters but clinical translation lags. Validation across cohorts needed.
Therapy Response Prediction
Subtypes correlate with PD-1 blockade resistance via EMT signatures (Wang et al., 2018). Basal subtypes show immune infiltration yet variable immunotherapy outcomes (Crispen and Kusmartsev, 2019). Prospective trials required for validation.
Essential Papers
Comprehensive molecular characterization of urothelial bladder carcinoma
John N. Weinstein, Rehan Akbani, Bradley M. Broom et al. · 2014 · Nature · 3.0K citations
Urothelial carcinoma of the bladder is a common malignancy that causes approximately 150,000 deaths per year worldwide. So far, no molecularly targeted agents have been approved for treatment of th...
Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology
Jeffrey S. Damrauer, Katherine A. Hoadley, David D. Chism et al. · 2014 · Proceedings of the National Academy of Sciences · 873 citations
Significance The identification of molecular subtype heterogeneity in breast cancer has allowed a deeper understanding of breast cancer biology. We present evidence that there are two intrinsic sub...
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Tom Powles, Joaquim Bellmunt, Éva Compérat et al. · 2021 · Annals of Oncology · 479 citations
Advances in diagnosis and treatment of bladder cancer
Antonio López-Beltrán, Michael S. Cookson, Brendan J. Guercio et al. · 2024 · BMJ · 355 citations
Abstract Bladder cancer remains a leading cause of cancer death worldwide and is associated with substantial impacts on patient quality of life, morbidity, mortality, and cost to the healthcare sys...
An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer
Sia V. Lindskrog, Frederik Prip, Philippe Lamy et al. · 2021 · Nature Communications · 344 citations
EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer
Li Wang, Abdel Saci, Péter M. Szabó et al. · 2018 · Nature Communications · 317 citations
Mechanisms of immune evasion in bladder cancer
Paul L. Crispen, Sergei Kusmartsev · 2019 · Cancer Immunology Immunotherapy · 235 citations
Reading Guide
Foundational Papers
Read Weinstein et al. (2014, TCGA) first for comprehensive luminal/basal discovery across 131 tumors; Damrauer et al. (2014) next for high-grade validation and breast analogy.
Recent Advances
Lindskrog et al. (2021) for non-muscle-invasive multi-omics subtypes; Powles et al. (2021 ESMO) for guideline integration; López-Beltrán et al. (2024) for diagnostic advances.
Core Methods
mRNA consensus clustering (Weinstein), single-sample gene expression predictors (Damrauer), integrated transcriptomics/proteomics (Lindskrog).
How PapersFlow Helps You Research Molecular Subtyping of Urothelial Carcinoma
Discover & Search
Research Agent uses searchPapers('molecular subtyping urothelial carcinoma luminal basal') to retrieve Weinstein et al. (2014) with 2992 citations, then citationGraph reveals Damrauer et al. (2014) and Lerner et al. (2016) clusters. exaSearch uncovers Lindskrog et al. (2021) for non-muscle-invasive subtypes. findSimilarPapers expands to 50+ related works.
Analyze & Verify
Analysis Agent applies readPaperContent on Weinstein et al. (2014) to extract luminal/basal gene signatures, then runPythonAnalysis with pandas clusters patient data by subtype survival. verifyResponse (CoVe) cross-checks claims against Damrauer et al. (2014); GRADE grading scores evidence as high for TCGA consensus.
Synthesize & Write
Synthesis Agent detects gaps in non-muscle-invasive subtyping post-Lindskrog et al. (2021), flags subtype contradictions between TCGA and Damrauer datasets. Writing Agent uses latexEditText for manuscript sections, latexSyncCitations integrates Weinstein/Damrauer references, latexCompile generates subtype consensus figure; exportMermaid diagrams luminal-basal gene overlaps.
Use Cases
"Compare survival curves for basal vs luminal subtypes in TCGA bladder cancer data"
Research Agent → searchPapers/TCGA → Analysis Agent → readPaperContent(Weinstein 2014) → runPythonAnalysis(pandas survival plots from supplementary data) → matplotlib KM curves output with p-values.
"Draft LaTeX review on urothelial subtype consensus meeting findings"
Synthesis Agent → gap detection(Lerner 2016) → Writing Agent → latexEditText(intro/methods) → latexSyncCitations(Weinstein/Damrauer) → latexCompile → PDF with consensus table.
"Find GitHub repos analyzing Damrauer 2014 bladder subtype code"
Research Agent → citationGraph(Damrauer) → paperExtractUrls → paperFindGithubRepo → githubRepoInspect(R code for centroid clustering) → runPythonAnalysis(reproduce basal classifier).
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(100 urothelial subtyping) → citationGraph → DeepScan(7-step: read/verify/synthesize per subtype) → structured report ranking luminal prognostic evidence. Theorizer generates hypotheses linking Wang et al. (2018) EMT to basal immunotherapy resistance via gap detection. DeepScan verifies subtype reproducibility across Lindskrog/TCGA datasets with CoVe checkpoints.
Frequently Asked Questions
What defines luminal and basal subtypes in urothelial carcinoma?
Luminal subtype expresses uroplakins, FGFR3 mutations; basal shows KRT5/6, immune markers (Weinstein et al., 2014; Damrauer et al., 2014).
What methods classify urothelial subtypes?
Consensus clustering on mRNA-seq (TCGA), single-sample predictors (Damrauer), multi-omics integration (Lindskrog et al., 2021).
What are key papers on urothelial subtyping?
Weinstein et al. (2014, TCGA, 2992 citations), Damrauer et al. (2014, 873 citations), Lerner et al. (2016 consensus, 210 citations).
What open problems exist in urothelial subtyping?
Subtype standardization across platforms, non-muscle-invasive validation, prospective therapy correlation trials (Lerner et al., 2016; Lindskrog et al., 2021).
Research Bladder and Urothelial Cancer Treatments with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Molecular Subtyping of Urothelial Carcinoma with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.